Recursion Pharmaceuticals Inc (RXRX)
9.26
-0.18
(-1.91%)
USD |
NASDAQ |
Jun 14, 16:00
9.18
-0.08
(-0.86%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash from Investing (Quarterly): -6.653M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -6.653M |
| December 31, 2023 | -2.488M |
| September 30, 2023 | -0.347M |
| June 30, 2023 | -2.053M |
| March 31, 2023 | -5.34M |
| December 31, 2022 | -7.979M |
| September 30, 2022 | 52.98M |
| June 30, 2022 | 4.94M |
| March 31, 2022 | 143.30M |
| Date | Value |
|---|---|
| December 31, 2021 | -52.24M |
| September 30, 2021 | -193.87M |
| June 30, 2021 | -6.212M |
| March 31, 2021 | -19.42M |
| December 31, 2020 | -4.591M |
| September 30, 2020 | -3.426M |
| June 30, 2020 | -0.039M |
| March 31, 2020 | -0.684M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-193.87M
Minimum
Sep 2021
143.30M
Maximum
Mar 2022
-6.124M
Average
-3.426M
Median
Sep 2020
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly and Co | -1.178B |
| Viking Therapeutics Inc | -459.79M |
| Actinium Pharmaceuticals Inc | -0.011M |
| Macrogenics Inc | 24.79M |
| Marinus Pharmaceuticals Inc | 20.88M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -102.30M |
| Cash from Financing (Quarterly) | 13.90M |
| Free Cash Flow | -330.63M |
| Free Cash Flow Per Share (Quarterly) | -0.4616 |
| Free Cash Flow to Equity (Quarterly) | -108.94M |
| Free Cash Flow to Firm (Quarterly) | -108.95M |
| Free Cash Flow Yield | -16.34% |